Precision Immunity: How Complement Inhibitors Are Rewriting the Rules of BiotherapyFor decades, managing chronic inflammatory and rare autoimmune disorders meant navigating a complex maze of broad immunosuppressive treatments. While these conventional therapies successfully dampened overactive immune responses, they frequently compromised overall host defense mechanisms, leaving patients vulnerable to secondary infections. Today, a major paradigm shift is reshaping immunology, centering on precision interventions designed to modulate specific cascading pathways of the innate immune system. At the forefront of this transformation are advanced therapeutic agents that intercept molecular signaling long before tissue damage occurs.This clinical momentum matches a robust trajectory of financial and industrial expansion across the sector. According to a Roots Analysis Market Summary, the global complement inhibitors market size, valued at USD 12.56 billion in 2025, is projected to reach USD 14.30 billion in 2026 and USD 28.65 billion by 2035, with a CAGR of 8% during the forecast period 2026 to 2035. This market is growing steadily, driven by the rise of next-generation complement targeting technologies and expanding therapeutic applications. Such steady financial scaling underscores a universal healthcare demand for targeted alternatives that offer higher efficacy with minimized systemic toxicity.Know More: https://www.rootsanalysis.com/reports/next-generation-complement-therapeutics-market.html